Ventyx Biosciences (NASDAQ:VTYX – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.08, Briefing.com reports. During the same quarter last year, the business earned ($0.62) earnings per share. Ventyx Biosciences Stock Performance VTYX stock traded up […]
Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Expectations By $0 08 EPS theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Ventyx Biosciences Reports Fourth Quarter And Full Year 2023 Financial Results And Highlights Recent Corporate Progress menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Ventyx to host virtual investor event on March 11th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002.
22.02.2024 - Results of the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis to be highlighted in oral presentation on February 22nd SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) - Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a . Seite 1